Health
Entresto’s effect ‘unclear’ in advanced chronic heart failure: study – Korea Biomedical Review
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard…
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard therapy for heart failure with reduced ejection fraction (HFrEF).
However, a recent study showed that the treatment did not…
Continue Reading
-
Noosa News16 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News19 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General15 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News15 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland